Mineralys Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Mineralys Therapeutics, Inc.'s free cash flow has increased -14.41% from $-166.41M last year to $-142.43M, signaling increasing performance

Mineralys Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Mineralys Therapeutics, Inc. has insufficient data to evaluate this check.

Mineralys Therapeutics, Inc. has a net cash position, so leverage is healthy.

Mineralys Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Mineralys Therapeutics, Inc. has insufficient data to evaluate this check.

Mineralys Therapeutics, Inc.'s short-term assets of $661.39M exceed its short-term liabilities of $15.11M

Mineralys Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Mineralys Therapeutics, Inc.'s return on equity of -27.92%, is lower than 15.00%, indicating bad performance

Mineralys Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Mineralys Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Mineralys Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Mineralys Therapeutics, Inc. has negative free cash flow, indicating cash burn

Mineralys Therapeutics, Inc.'s yearly earnings has increased -13.02% since last year from $-177.81M to $-154.65M, signaling increasing performance

Mineralys Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -26.87% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Mineralys Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Mineralys Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Mineralys Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Mineralys Therapeutics, Inc. is overvalued relative to its fair value price of 0.88 based on Discounted Cash Flow model

Mineralys Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mineralys Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Mineralys Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Mineralys Therapeutics, Inc. has insufficient data to evaluate this check.

Mineralys Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mineralys Therapeutics, Inc. has a price-to-book ratio of 3.55x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Mineralys Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue